Vertex Pharmaceuticals (NASDAQ: VRTX) hasn't witnessed the crazy price spike that some other stocks have had in the new bull ...

From a $100 billion AI investment to a cancer vaccine trial, check out this week's awesome tech stories from around the web.

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

No surprise that Apple’s annual September event included a brand new iPhone. This one, dubbed iPhone 16, was "designed around ...

A groundbreaking review how AI is revolutionizing the field of emotional recognition, promising to transform everything from ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

An innovative approach to healthcare, precision medicine is a new medical model that takes into account individual ...

Design My Trip’ helps travelers plan their trips to Thailand within seconds, supporting the country’s international tourism ...

Some people of West African of descent face a higher risk of renal failure. New drugs based on gene research may help right ...

As global markets rebound from recent sell-offs, technology stocks have led the charge, significantly outpacing their value counterparts. With the S&P 500 Index recovering from its steepest decline ...

Design My Trip' helps travelers plan their trips to Thailand within seconds, supporting the country's international tourism ...